Myeloid Leukemia News and Research

RSS

Myeloid Leukemia is an aggressive (fast-growing) disease in which too many myeloblasts (immature white blood cells that are not lymphoblasts) are found in the bone marrow and blood. Also called acute myeloblastic leukemia, acute myelogenous leukemia, acute nonlymphocytic leukemia, AML, and ANLL.

Salk professor receives inaugural Sjöberg Prize for groundbreaking cancer research

Salk Professor Tony Hunter, who holds an American Cancer Society Professorship, has been awarded $500,000 as part of the $1 million Royal Swedish Academy of Sciences' inaugural Sjöberg Prize for Cancer Research for "groundbreaking studies of cellular processes that have led to the development of new and effective cancer drugs."

14 Feb 2017

New drug offers hope for patients with bladder cancer

A bladder cancer drug discovered and developed at The University of Kansas Cancer Center is set to become its first cancer drug to go from bench to bedside.

10 Feb 2017

Researchers develop computer machine-learning model to predict remission or relapse in AML patients

Researchers have developed the first computer machine-learning model to accurately predict which patients diagnosed with acute myelogenous leukemia, or AML, will go into remission following treatment for their disease and which will relapse.

9 Feb 2017

Common drug for autoimmune disease may increase risk of myeloid neoplasms

Mayo Clinic researchers have found that azathioprine, a drug commonly used to treat autoimmune disease, may increase the risk of myeloid neoplasms.

3 Feb 2017

Researchers design antibody that recognizes and destroys blood cancer stem cells

A protein-sugar molecule, CD99, occurs more frequently than normal on stem cells responsible for blood cancers, including acute myeloid leukemia (AML) and the related myelodysplastic syndromes.

25 Jan 2017

Roswell Park study provides new insights into gene mutations that can lead to cancer

Predisposition to cancer and cancer progression can result from gene mutations that cause elevated rates of genetic damage.

11 Jan 2017

Persistent infection in infant reveals mutation that helps bacteria tolerate antibiotic therapy

The quest to understand a prolonged infection in an infant being treated for leukemia has led to the St. Jude Children's Research Hospital discovery of a mutation that allows bacteria to tolerate normally effective antibiotic therapy. The report appears today in the scientific journal mBio.

3 Jan 2017

Researchers identify possible treatment targets for myelodysplasia syndromes

Cincinnati Children's researchers report in Nature Immunology a new mechanism that controls blood cell function and several possible molecular targets for treating myelodysplasia syndromes (MDS) - a group of pre-malignant disorders in which bone marrow does not produce enough healthy blood cells.

30 Dec 2016

UC researchers uncover obesity-related protein's role in leukemia development

Cancer researchers at the University of Cincinnati College of Medicine have found an obesity-associated protein's role in leukemia development and drug response which could lead to more effective therapies for the illness.

22 Dec 2016

FDA awards accelerated approval to new ovarian cancer drug

The U.S. Food and Drug Administration today granted accelerated approval to Rubraca (rucaparib) to treat women with a certain type of ovarian cancer.

19 Dec 2016

Newborns with CMV may have increased risk of developing acute lymphocytic leukemia

Newborns with congenital cytomegalovirus (CMV) -- a common virus in the herpes family -- may have an increased risk of developing acute lymphocytic leukemia (ALL), according to new research published online today in Blood, the Journal of the American Society of Hematology. The study suggests the risk is even greater in Hispanic children.

15 Dec 2016

New technology that increases Natural Killer cells to stop cancers gets licensed

Our bodies contain Natural Killer (NK) cells - an army that stops cancers and viruses before they can make us sick.

15 Dec 2016

Personalized cancer vaccine improves outcomes for patients with AML, clinical study shows

A personalized cancer vaccine markedly improved outcomes for patients suffering from acute myeloid leukemia (AML), a potentially lethal blood cancer, in a clinical trial led by investigators at Beth Israel Deaconess Medical Center.

9 Dec 2016

Stem cell-based risk scoring tool could predict AML patient’s response to standard treatment

Leukemia researchers at Princess Margaret Cancer Centre have developed a 17-gene signature derived from leukemia stem cells that can predict at diagnosis if patients with acute myeloid leukemia (AML) will respond to standard treatment.

8 Dec 2016

New research reveals role of two genetic mutations in subset of acute myeloid leukemia

Two genetic mutations known to play a role in many solid cancers might also help explain why a subset of acute myeloid leukemia (AML) patients develop the disease, according to new research from The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.

7 Dec 2016

Experimental T-cell therapy shows promise in preventing AML relapse

Fred Hutchinson Cancer Research Center announced promising results from an early trial in which patients with high-risk acute myeloid leukemia received genetically engineered immune cells.

6 Dec 2016

Simple, coordinated approach can improve chances of survival for high-risk AML patients

New research shows that quickly identifying patients with high-risk acute myeloid leukemia (AML), and speeding the process to find them a stem cell donor and performing the transplant earlier, can significantly improve their chances of surviving for at least two years after diagnosis without a relapse.

5 Dec 2016

New study finds smoking cessation at any age reduces risk of death

Tobacco use continues to be a major cause of cancer and premature death. Most studies of cigarette smoking and mortality have focused on middle-aged populations, with fewer studies examining the impact of tobacco cessation on disease and mortality risk among the elderly.

30 Nov 2016

Cancer gene mutations can predict response to less intensive treatment in AML patients

Patients with the most lethal form of acute myeloid leukemia (AML) - based on genetic profiles of their cancers - typically survive for only four to six months after diagnosis, even with aggressive chemotherapy.

23 Nov 2016

Implementation of large-scale genomic tumor profiling viable but faces several challenges

Researchers leading the largest genomic tumor profiling effort of its kind say such studies are technically feasible in a broad population of adult and pediatric patients with many different types of cancer, and that some patients can benefit by receiving precision drugs targeted to their tumors' mutations or being enrolled in clinical trials.

18 Nov 2016